Introduction
A major public health threat, osteoporosis is estimated to affect 44 million Americans.
About 40%-50% of women and 13%-22% of men are at risk of having an osteoporotic fracture in their lifetime [1] . Burge with an anticipated increase to $25.3 billion in 2025, given the aging population [2] .
In addition to the substantial cost burden, hip fractures are also associated with a high mortality rate. Approximately 24% of hip fracture patients ≥50 years of age die in the year following their fracture [3] . As expensive as hip fractures are, Gabriel et al. found that they represent only 37% of the total incremental cost of all moderate-trauma fractures combined [4] .
While hip fractures remain a key driver of osteoporosis-related costs, some research indicates that osteoporosis-related, non-hip fractures, such as those of the spine, wrist/forearm, pelvis, humerus, and leg, are more prevalent than hip fractures [2, 5] . Burge et al. report that, of the 2 million osteoporotic fractures estimated in 2005, hip fractures account for only 14%, while spine fractures represent 27%, and the remaining 59% includes fractures of the wrist, pelvis, and other sites (clavicle, scapula, humerus, carpal bone, metacarpal, other femur, patella, tibia and fibula) [2] . Much is known about the health and economic impact of hip and vertebral fractures; however, to accurately characterize the burden of all osteoporotic fractures, further research is needed on the clinical and economic burden associated with NHNV fractures, which account for more than half of the total number of osteoporotic fractures.
Numerous studies conducted in various countries [6] [7] [8] [9] [10] [11] using both retrospective [6] and prospective study designs [7] [8] [9] , as well as case-control comparisons [10, 12, 13] have analyzed Page 6 of 27 the cost of hip fractures. While there is growing literature examining the cost of vertebral and non-vertebral fractures, many of the studies estimate cost based on economic models instead of data from real-world practice settings [2, [14] [15] [16] [17] . Other studies are confined to a specific gender or age cohort [12, 14, 18] or use data drawn from a single county in the US [4, 19] . Lack of comparison cohorts makes it difficult to gauge the incremental cost associated with these fractures [20] . To better understand the economic burden of osteoporotic fractures in our healthcare system, this study estimated the incremental cost associated with closed hip, vertebral, and NHNV fractures by comparing healthcare cost in the first year following the fracture among fracture patients and their age-gender-region-comorbidity-matched controls who were fracture-free during the study period. Additionally, given that NHNV fractures are more prevalent in the younger population [20] , costs were analyzed separately for patients of 50-64 years and ≥65 years. do not improve the positive predictive value of probable fractures [21] . In an effort to limit the analyses to osteoporotic fractures, open fractures and closed cervical and sacrum/coccyx fractures were excluded as they are more often associated with trauma rather than osteoporosis.
Methods

Data Source
A list of ICD-9-CM fracture diagnosis codes is provided in Table 1 .
The first observed fracture during the index period was denoted as the index fracture.
Eligible patients were required to be continuously enrolled 6 months prior to, and 12 months after the index fracture. Patients were excluded if they had any fracture during the pre-period or did not have complete medical and pharmacy data available during the study period. Six fracture cohorts were selected and analyzed individually: hip, vertebral, and NHNV, for patients 50-64 years and ≥65 years.
To estimate the incremental healthcare costs associated with fractures, comparison groups were identified that consisted of enrollees who were fracture-free during the study period.
For each of the 6 fracture cohorts, patients were matched to controls based on exact age, gender, and region, as well as ± 3 diagnostic cluster score (DCS). The diagnosis clusters (version 4. [22, 23] . A patient-level summary score based on the total count of diagnostic clusters was generated in this study. The highest possible DCS was 120 for patients <65 and 135 for patients ≥65.
Matching was achieved through a 2-stage process. Fracture patients and controls were first matched 1:10 based on exact age, gender, and region. Subsequently, the controls were assigned the same index date as that of their matched fracture patient. The controls were Page 9 of 27 required to be continuously enrolled 6 months prior to and 12 months after the acquired index date. DCS was calculated from the claims during the 6-month pre-period. A 1:1 matching was performed to pair fracture patients with controls within ± 3 DCS.
Outcomes
The outcome of this study was the incremental healthcare costs associated with hip, vertebral, and NHNV fractures during the first year following the fracture. A 12 month period was chosen because fractures, especially in the elderly, can have long-term effects and treatments, such as rehabilitation and physical therapy, which can extend beyond 3 to 6 months.
Total healthcare costs were assessed separately for the fracture and the control cohorts. The difference in healthcare cost between the comparison cohorts served as an estimate of the incremental cost associated with fracture. Costs were also categorized into inpatient, outpatient, and pharmacy expenses to depict the care setting of fracture-related expenditures. Outpatient expenses included physician visits and other services rendered in the outpatient setting.
A generalized linear model with the variance proportional to the mean and a log link was used to estimate total incremental healthcare cost associated with fracture, adjusting for differences in the DCS and pre-period medical expenditures. Additionally, fracture-associated confounding conditions, such as endocrine disease, cancer, alcoholism, and rheumatoid arthritis were included in the multivariate models where significant differences were detected between groups. Due to differences in fracture type and age group, confounding conditions varied for the 6 models, as shown in Table 2 .
Cost was defined as the total net payment from paid and adjudicated claims, including provided under capitation insurance coverage were estimated from encounter records using fee-for-service equivalents defined by procedure code and region.
Results
Patient Characteristics
Six study samples were identified and over 89% of fracture patients were matched to a control. Unmatched patients were removed from the study. Comparison of pre-and postmatching patient profiles indicated the matched samples resembled the pre-match samples. Similarly, but to a lesser extent, NHNV fracture was the most prevalent fracture in the ≥65 cohort, comprising 55% of total fractures, followed by hip (29%) and vertebral (16%) fractures. The ratio between NHNV and hip fracture was 2:1. Prior to their fracture, 14% of fracture patients were diagnosed with endocrine disease.
Cancer, other than breast or bone cancer, was detected in 10%-14% of both age fracture cohorts.
Between 5%-6% of fracture patients had thyroid disease. The prevalence rates of other confounding conditions in the fracture cohorts were lower than 4%. The prevalence of confounding conditions among the 6 comparison cohorts are displayed in Table 2 their controls. Given that some of these conditions can be costly, their potential impacts on first-year cost following fracture were subsequently controlled for through multivariate models.
Cost of Fractures
The unadjusted mean healthcare costs during the first year following fracture were 1-4 times higher for the fracture patients than their matched controls depending on the fracture type (Table 3) 
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In the 50-64 cohort, hip fracture patients incurred 69% ($21,423) of their total incremental cost from inpatient services, followed by 23% ($7,277) from outpatient services and 8% ($2,347) from pharmacy. Over half of the total incremental cost of vertebral fractures was spent on hospitalizations ($9,783), while one third was spent on outpatient services ($6,480), and 13% ($2,340) on pharmacy. Outpatient services (48%, $5,028) contributed slightly more than inpatient services (44%, $4,620) to incremental cost for NHNV fracture patients, leaving pharmacy expenses at 9% ($905).
For the ≥65 cohort, inpatient services accounted for 58% ($9,740) of the incremental cost among hip fracture patients, followed by outpatient (39%, $6,592) and pharmacy (3%, $491). While NHNV fracture had the lowest incremental first-year cost among the 3 fracture types, it was 10 times more prevalent than hip fracture in the 50-64 cohort. We estimated the total firstyear fracture costs per 100,000 lives insured by private health insurance or Medicare by applying
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our cost estimates to the fracture prevalence rates per 100,000 women covered in these data sources. Fig. 3 presents first year post-fracture healthcare cost associated with each type of fracture and age group for a 100,000 member health plan. The estimated cost was calculated by multiplying the estimated number of patients with each fracture type per 100,000 patients in MarketScan during the study period by the estimated fracture cost during the first year. The first-year incremental cost per 100,000 lives for the 50-64 cohort was $1.5 million for NHNV fracture, $0.5 million for hip fracture, and $0.3 million for vertebral fracture. The cost of NHNV fractures contributed 66% of the total fracture cost for the 50-64 cohort. This far exceeded the 13% and 21% estimated for hip and vertebral fractures, respectively, for the same age cohort.
Total first-year NHNV, hip, and vertebral fracture-related cost per 100,000 lives for the ≥65 cohort was $14.8 million, $21.2 million, and $4.8 million, of which 52% was accounted for by hip fractures followed by 36% due to NHNV and 12% from vertebral fractures.
Discussion
While previous research has demonstrated the economic burden associated with osteoporotic hip and vertebral fractures, this paper is one of the first to highlight the significant proportion of osteoporotic fracture costs that are due specifically to NHNV fractures. The adjusted first-year healthcare costs associated with fractures were highest for hip fracture patients, followed by vertebral and NHNV fractures. However, the overall cost impact of NHNV fractures matched or exceeded that of hip fractures after accounting for the prevalence rates. NHNV fractures represented 82% and 55% of all fractures identified in the matched samples for the 50-64 cohort and the ≥65 cohort, respectively. These fractures accounted for 69% and 38% of the total first-year post-fracture cost in each age cohort, respectively.
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Our results are consistent with previous findings on the economic burden of osteoporotic fractures [4, 6, [11] [12] 15, 17, 20] , with some variations due to differences in research design.
Ohsfeldt et al. assessed fracture-related medical cost in the first year following non-vertebral fracture using the MarketScan ® databases [20] . Costs were estimated based on resource utilization identified through diagnoses and procedures on medical claims related to fractures.
Unit cost was assigned according to various standard fee schedules. After adjusting to 2006 dollars, the estimated costs of NHNV fracture were $7,093 for the 45-64 age cohort and $5,621
for the ≥65 cohort. These figures are roughly comparable to our estimates ($9,183 and $6,106, respectively) given that the Ohsfeldt et al. study may have failed to account for cost for outpatient pharmacy. However, the inflation-adjusted cost of hip fracture was $37,567 for the 45-64 cohort, and $30,038 for the ≥65 cohort, both of which are higher than those of our study ($26,545 and $15,196, respectively). To some extent, the lower figures for hip fracture from our study are not completely unexpected since the incremental cost estimation approach can yield lower estimates as it may over-adjust for unobserved differences between cases and controls [20] . The direct measurement method used by Oshfeldt et al., on the other hand, may overestimate costs because both primary and secondary diagnoses were used to identify resource utilization and, as a result, the costs of coincidental treatment for comorbid conditions during an episode of care for fracture may be inadvertently attributed as fracture-related cost. The hip fracture cost for the ≥65 cohort in our study was close to the estimate of $16,834 from another study examining the cost of hip fracture among elderly women [10] . fracture, and $3,810/"wrist-like" fracture. These estimates are lower than our estimates, in part, because these numbers were expressed in 1995 dollars and ours were valued in 2006 dollars.
However, the underlying differences are likely due to the omission of several important categories of healthcare cost, including nursing home, outpatient prescription drugs, durable medical equipment, ambulance, and outpatient services provided by allied health professionals in the Gabriel et al. study. Using samples from a single county in Minnesota limited the ability of the study to generalize its findings, whereas our samples were drawn from 166 million covered lives in the working population and 33 million retirees in the US Medicare population. Other studies using economic models provided wide ranges of estimates for the first-year cost after hip fracture, from US $10,000/year in the Netherlands [11] to $69,389 for elderly male veterans covered by Medicare in the US [6] .
Our estimated medical costs for patients 50-64 were consistently higher than that of the ≥65 cohort across all fracture types. This is partly due to the lower reimbursement rates paid by
Medicare than commercial payers. Additionally, readmission within 60 days is covered by the payment from the first admission in Medicare, while commercial payers typically pay in full.
Medicare pays for the first 21 days when a patient is transferred to a skilled nursing facility after hospitalizations. Since no payment is required from the supplemental side, which is the data source for MarketScan Medicare databases, no claim for services is incurred. As a result, the overall medical cost of the Medicare population may be slightly underestimated when Medicare pays 100% of the healthcare event. However, the data presented here accurately reflected the costs to employers and health plans for Medicare patients. Our inclusion requirement of having 1 year of data post-fracture excluded patients who died shortly after their fracture, particularly
Page 16 of 27
those who had a hip fracture. The exclusion may further explain the lower costs observed among Medicare patients in this study.
There are limitations inherent in using an administrative healthcare database.
Information on race, socioeconomic status, anthropometrics, and mortality were unavailable.
We were only able to capture clinically-diagnosed fractures and excluded patients with sub-clinical fractures that did not reach medical attention. While we identified fracture by diagnosis on non-radiology claims, we did not require patients to have fracture-related procedures during the period surrounding the initial fracture diagnosis. Ray et al. suggested that using only hospital and ER diagnosis of fracture in claim data yielded a positive predictive value (PPV) of 90% for hip, 89% for humerus, 88% for radius/ulna, 85% for pelvis, and 70% for tibia/fibula fractures, which are lower than the overall 94% PPV when both diagnosis and procedure codes are required [21] . Consequently, we may have classified some patients into the fracture cohorts who did not have fractures and thus underestimated the cost of fracture. This, however, does not change the principle conclusion of the study.
Closed fracture diagnoses were used to rule out trauma-related fractures but we were unable to review patient's medical records to validate this assumption. We may also have underestimated the prevalence of vertebral and hip fractures that were coded as pathological fractures since these codes were excluded from this study under the assumption that they were likely due to a malignancy or rare disease. A recent study indicated that half of patients with a pathologic fracture diagnosis of the vertebrae or hip had no evidence of malignancy [24] . The fracture cohorts had higher DCS than the controls post-matching, indicating they were sicker than the controls prior to entering the study. These differences were controlled through multivariate regressions. Finally, uninsured fracture patients and those covered by Medicaid or 
